ACTU (Actuate Therapeutics) Days Payable: 0.00 (As of Mar. 2026)


ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.82
View Full Analysis

What is Actuate Therapeutics Days Payable?

Actuate Therapeutics ACTU -14.29% 14 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates ACTU with a GF Score™ of 14/100. Among 707 Biotechnology companies, Actuate Therapeutics ranks worse than 141442.57% on this metric.

Actuate Therapeutics's average Accounts Payable for the three months ended in Mar. 2026 was $1.36 Mil. Actuate Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for Actuate Therapeutics's Days Payable or its related term are showing as below:

ACTU's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.76
* Ranked among companies with meaningful Days Payable only.

Actuate Therapeutics's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Actuate Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Actuate Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actuate Therapeutics Days Payable Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Days Payable
0.00 0.00 0.00 0.00

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ACTU vs AURX, ESLA, MGX: Days Payable Comparison

For the Biotechnology subindustry, Actuate Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actuate Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Actuate Therapeutics's Days Payable falls into.


ACTU
14GF Score
Actuate Therapeutics Inc ACTU
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actuate Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Actuate Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (1.921 + 1.524) / 2 ) / 0*365
=1.7225 / 0*365
=N/A

Actuate Therapeutics's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

Days Payable (Q: Mar. 2026 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2025 ) + Accounts Payable (Q: Mar. 2026 )) / count ) / Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=( (1.524 + 1.201) / 2 ) / 0*365 / 4
=1.3625 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Actuate Therapeutics (ACTU) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Actuate Therapeutics and its competitors. According to the industry distribution chart, Actuate Therapeutics ranks #999999 out of 707 companies in the Biotechnology industry.
Is Actuate Therapeutics' Days Payable too high?
Actuate Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Actuate Therapeutics ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Days Payable compare to AURX and ESLA?
According to the Biotechnology industry distribution chart, Actuate Therapeutics ranks #999999 out of 707 companies for Days Payable. This places Actuate Therapeutics in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Actuate Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actuate Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Days Payable of 0.00. The current Days Payable is 0.00. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.82
Price